Synthesis of potential prodrug systems for reductive activation. Prodrugs for anti-angiogenic isoflavones and VEGF receptor tyrosine kinase inhibitory oxindoles

Tetrahedron

Volumn 65, Issue 25, 2009, Pages 4894-4903

  Blanche, Emilie A ^a   Maskell, Lesley ^b   Colucci, Marie A ^c   Whatmore, Jacqueline L ^b   Moody, Christopher J ^a,c  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b PENINSULA MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 [(3,5 DIMETHYLPYRROL 2 YL)METHYLIDENYL]INDOLIN 2 ONE; 1,4 BENZOQUINONE DERIVATIVE; 3 [(3,5 DIMETHYLPYRROL 2 YL)METHYLIDENYL] 1 (2 NITROPHENYLACETYL)INDOLIN 2 ONE; 3 [(3,5 DIMETHYLPYRROL 2 YL)METHYLIDENYL] 1 (3 NITROPHENYLACETYL)INDOLIN 2 ONE; 3 [(3,5 DIMETHYLPYRROL 2 YL)METHYLIDENYL] 1 (4 NITROBENZYL)INDOLIN 2 ONE; 3 [(3,5 DIMETHYLPYRROL 2 YL)METHYLIDENYL] 1 [2 (2 NITROPHENYL) 2,2 DIMETHYLACETYL]INDOLIN 2 ONE; 3 [(3,5 DIMETHYLPYRROL 2 YL)METHYLIDENYL] 1 [3 METHYL 3 (3,6 DIMETHYL 1,4 BENZOQUINON 2 YL)BUTAN 1 OYL]INDOLIN 2 ONE; 3 [(3,5 DIMETHYLPYRROL 2 YL)METHYLIDENYL] 6 (2 NITROPHENYLACETOXY)INDOLIN 2 ONE; 3 [(3,5 DIMETHYLPYRROL 2 YL)METHYLIDENYL] 6 (4 NITROBENZYLOXY) INDOLIN 2 ONE; 4 METHYL 7 (3 NITROPHENYLACETOXY)COUMARIN; 4 METHYL 7 (4 NITROBENZYLOXY)COUMARIN; 4 NITROBENZOIC ACID; 5 HYDROXY 3 (4 METHOXYPHENYL) 7 (2 NITROPHENYLACETOXY)CHROMEN 4 ONE; 5 HYDROXY 3 (4 METHOXYPHENYL) 7 (3 NITROPHENYLACETOXY)CHROMEN 4 ONE; 5 HYDROXY 3 (4 METHOXYPHENYL) 7 (4 NITROBENZYLOXY)CHROMEN 4 ONE; 5 HYDROXY 3 (4 METHOXYPHENYL) 7 [2 (2 NITROPHENYL) 2,2 DIMETHYLACETOXY]CHROMEN 4 ONE; 5 HYDROXY 3 (4 METHOXYPHENYL) 7 [3 METHYL 3 (3,6 DIMETHYL 1,4 BENZOQUINON 2 YL)BUTAN 1 OYLOXY]CHROMEN 4 ONE; 6 [3 METHYL 3 (3,6 DIMETHYL 1,4 BENZOQUINON 2 YL)BUTANOYLOXY] 3 [(3,5 DIMETHYLPYRROL 2 YL)METHYLENE] INDOLIN 2 ONE; 6 BENZYLOXY 3 [(3,5 DIMETHYLPYRROL 2 YL)METHYLIDENYL] INDOLIN 2 ONE; 6 HYDROXY 3 [(3,5 DIMETHYLPYRROL 2 YL)METHYLIDENYL] INDOLIN 2 ONE; 7 BENZYLOXY 5 HYDROXY 3 (4 METHOXYPHENYL)CHROMEN 4 ONE; BIOCHANIN A; BUTYRIC ACID DERIVATIVE; ISOFLAVONE DERIVATIVE; PHENYLACETIC ACID DERIVATIVE; PHENYLACETYLENE; SEMAXANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SYNTHESIS; PRIORITY JOURNAL;

EID: 65549161379     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tet.2009.04.014     Document Type: Article

References (52)

1. Melton R.G., and Knox R.J. Enzyme Prodrug Strategies for Cancer Therapy (1999), Kluwer Academic/Plenum, New York, NY
2. Jaffar M., Williams K.J., and Stratford I.J. Adv. Drug Delivery Rev. 53 (2001) 217-228
3. Naylor M.A., and Thomson P. Mini-Rev. Med. Chem. 1 (2001) 17-29
4. Skelly J.V., Knox R.J., and Jenkins T.C. Mini Rev. Med. Chem. 1 (2001) 293-306
5. Wardman P. Curr. Med. Chem. 8 (2001) 739-761
6. Denny W.A. Curr. Pharm. Des. 8 (2002) 1349-1361
7. Atwell G.J., Sykes B.M., O'Connor C.J., and Denny W.A. J. Med. Chem. 37 (1994) 371-380
8. Carpino L.A., Triolo S.A., and Berglund R.A. J. Org. Chem. 54 (1989) 3303-3310
9. Amsberry K.L., and Borchardt R.T. Pharm. Res. 8 (1991) 323-330
10. Weerapreeyakul N., Hollenbeck R.G., and Chikhale P.J. Bioorg. Med. Chem. Lett. 10 (2000) 2391-2395
11. Killian D.M., and Chikhale P.J. J. Neurochem. 76 (2001) 966-974
12. Li Z.R., Han J.Y., Jiang Y.Y., Browne P., Knox R.J., and Hu L.Q. Bioorg. Med. Chem. 11 (2003) 4171-4178
13. Jiang Y.Y., Han J.Y., Yu C.Z., Vass S.O., Searle P.F., Browne P., Knox R.J., and Hu L.Q. J. Med. Chem. 49 (2006) 4333-4343
14. Hay M.P., Atwell G.J., Wilson W.R., Pullen S.M., and Denny W.A. J. Med. Chem. 46 (2003) 2456-2466
15. Hay M.P., Wilson W.R., and Denny W.A. Bioorg. Med. Chem. 13 (2005) 4043-4055
16. Zaarur N., Gabai V.L., Porco J.A., Calderwood S., and Sherman N.Y. Cancer Res. 66 (2006) 1783-1791
17. Lee H.H., Palmer B.D., Wilson W.R., and Denny W.A. Bioorg. Med. Chem. Lett. 8 (1998) 1741-1744
18. Parveen I., Naughton D.P., Whish W.J.D., and Threadgill M.D. Bioorg. Med. Chem. Lett. 9 (1999) 2031-2036
19. Reigan P., Edwards P.N., Gbaj A., Cole C., Barry S.T., Page K.M., Ashton S.E., Luke R.W.A., Douglas K.T., Stratford I.J., Jaffar M., Bryce R.A., and Freeman S. J. Med. Chem. 48 (2005) 392-402
20. Ferrer S., Naughton D.P., Parveen I., and Threadgill M.D. J. Chem. Soc., Perkin Trans. 1 (2002) 335-340
21. Ferrer S., Naughton D.P., and Threadgill M.D. Tetrahedron 59 (2003) 3437-3444
22. Zhang Z., Tanabe K., Hatta H., and Nishimoto S. Org. Biomol. Chem. 3 (2005) 1905-1910
23. Thomson P., Naylor M.A., Everett S.A., Stratford M.R.L., Lewis G., Hill S., Patel K.B., Wardman P., and Davis P.D. Mol. Cancer Ther. 5 (2006) 2886-2894
24. Moody C.J., and Swann E. Farmaco 52 (1997) 271-279
25. Naylor M.A., Swann E., Everett S.A., Jaffar M., Nolan J., Robertson N., Lockyer S.D., Patel K.B., Dennis M.F., Stratford M.R.L., Wardman P., Adams G.E., Moody C.J., and Stratford I.J. J. Med. Chem. 41 (1998) 2720-2731
26. Everett S.A., Naylor M.A., Barraja P., Swann E., Patel K.B., Stratford M.R.L., Hudnott A.R., Vojnovic B., Locke R.J., Wardman P., and Moody C.J. J. Chem. Soc., Perkin Trans. 2 (2001) 843-860
27. Swann E., Moody C.J., Stratford M.R.L., Patel K.B., Naylor M.A., Vojnovic B., Wardman P., and Everett S.A. J. Chem. Soc., Perkin Trans. 2 (2001) 1340-1345
28. Everett S.A., Swann E., Stratford M.R.L., Patel K.B., Naylor M.A., Tian N., Newman R.G., Vojnovic B., Moody C.J., and Wardman P. Biochem. Pharmacol. 63 (2002) 1629-1639
29. Ferrer S., Naughton D.P., and Threadgill M.D. Tetrahedron 59 (2003) 3445-3454
30. Couch G.D., Burke P.J., Knox R.J., and Moody C.J. Tetrahedron 64 (2008) 2816-2823
31. Whatmore J.L., Swann E., Barraja P., Newsome J.J., Bunderson M., Beall H.D., Tooke J.E., and Moody C.J. Angiogenesis 5 (2002) 45-51
32. Maskell L., Blanche E.A., Colucci M.A., Whatmore J.L., and Moody C.J. Bioorg. Med. Chem. Lett. 17 (2007) 1575-1578
33. Folkman J. N. Engl. J. Med. 285 (1971) 1182-1186
34. Folkman J. Ann. Surg. 175 (1972) 409-416
35. Claffey K.P., and Robinson G.S. Cancer Metastasis Rev. 15 (1996) 165-176
36. Ferrara N., and DavisSmyth T. Endocr. Rev. 18 (1997) 4-25
37. Fujita Y., Abe R., and Shimizu H. Curr. Pharm. Des. 14 (2008) 3820-3834
38. Zhou J.R., Mukherjee P., Gugger E.T., Tanaka T., Blackburn G.L., and Clinton S.K. Cancer Res. 58 (1998) 5231-5238
39. He H., Venema V.J., Guo X.L., Venema R.C., Marrero M.B., and Caldwell R.B. J. Biol. Chem. 274 (1999) 25130-25135
40. Sun L., Tran N., Tang F., App H., Hirth P., McMahon G., and Tang C. J. Med. Chem. 41 (1998) 2588-2603
41. Sun L., Tran N., Liang C.X., Tang F., Rice A., Schreck R., Waltz K., Shawver L.K., McMahon G., and Tang C. J. Med. Chem. 42 (1999) 5120-5130
42. Fong T.A.T., Shawver L.K., Sun L., Tang C., App H., Powell T.J., Kim Y.H., Schreck R., Wang X.Y., Risau W., Ullrich A., Hirth K.P., and McMahon G. Cancer Res. 59 (1999) 99-106
43. Mendel D.B., Laird A.D., Smolich B.D., Blake R.A., Liang C.X., Hannah A.L., Shaheen R.M., Ellis L.M., Weitman S., Shawver L.K., and Cherrington J.M. Anti-Cancer Drug Des. 15 (2000) 29-41
44. Zheng A., Shan D., and Wang B. J. Org. Chem. 64 (1999) 156-161
45. Corwin A.H., and Krieble R.H. J. Am. Chem. Soc. 63 (1941) 1829-1834
46. Beckett A.H., Daisley R.W., and Walker J. Tetrahedron 24 (1968) 6093-6109
47. Pitts M.R., Harrison J.R., and Moody C.J. J. Chem. Soc., Perkin Trans. 1 (2001) 955-977
48. James A.L., Perry J.D., and Stanforth S.P. J. Heterocycl. Chem. 43 (2006) 515-517
49. Siegel D., and Ross D. Free Radical Biol. Med. 29 (2000) 246-253
50. Gustafson D.L., Siegel D., Rastatter J.C., Merz A.L., Parpal J.C., Kepa J.K., Ross D., and Long M.E. J. Pharmacol. Exp. Ther. 305 (2003) 1079-1086
51. King F.E., and Jurd L. J. Chem. Soc. (1952) 3211-3215
52. Koolwijk P., vanErck M.G.M., deVree W.J.A., Vermeer M.A., Weich H.A., Hanemaaijer R., and vanHinsbergh V.W.M. J. Cell Biol. 132 (1996) 1177-1188